Known as secondary CNS lymphoma or SCNSL, it can occur during or after initial chemotherapy treatment and is often associated with disappointing outcomes. Although it only occurs in about 4% to 6% of
"Secondary CNS lymphoma is a challenging condition associated with shorter survival rates in a significant number of patients," said Juan Alderuccio, MD, a Sylvester hematologist and lymphoma specialist, and the manuscript's corresponding author. "For patients experiencing accompanying systemic with CNS lymphoma relapse, their prognosis can be especially bleak. However, there may be hope on the horizon for these patients with development of potentially effective therapies such as antiCD19 CAR T-cell therapy," Alderuccio said, explaining that this approach has been associated with encouraging preliminary efficacy. However, the duration of response is presently unknown.